James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found New Leaf in 2005. Jim will change his status to Venture Partner in NLV-II] with the closing of the new fund. In this role, Jim will work full-time as a senior member of the NLV investment team working on new investments, and he will continue with full oversight and portfolio management responsibilities for NLV-I and NLV-II. Jim is currently on the boards of directors of Chimerix (NASDAQ: CMRX, former Chairman) and Tioga. He was previously on the boards of Intarcia Therapuetics (now currently a Board observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Science and Technology Officer for GlaxoSmithKline (“GSK”). From 1995 to 2001, he led Global Research and Development, Information Technology and Product Strategy and was a member of the board of directors of Glaxo Wellcome plc. From 1988 to 1995 Jim was Vice President, Research and Senior Vice-President R & D for the U.S. subsidiary of Glaxo. During his nearly 13 years with the Company, he oversaw the discovery, development and/or registration of over 20 products marketed by GSK, including those for: HIV, hepatitis B, asthma/COPD, migraine, BPH, irritable bowel syndrome, smoking cessation, depression, chemotherapy-induced nausea and vomiting, breast cancer, herpes and malaria. Prior to GSK, Jim was Professor of Medicine, Chief of the Division of Clinical Pharmacology and Principal Investigator on studies of mechanisms of cancer and inflammation at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Medical Oncology fellowship. Jim received his M.D. and Ph.D. (Biochemistry) degrees from the University of Miami, was selected a Searle Scholar a